ClinicalTrials.gg
CompletedNCT01624285Updated Nov 3, 2026Results posted

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

A Phase 2 interventional study of sorafenib tosylate and placebo in Adult Primary Hepatocellular Carcinoma, Localized Resectable Adult Primary Liver Cancer and Localized Unresectable Adult Primary Liver Cancer, sponsored by Jonsson Comprehensive Cancer Center. Completed at 21 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Jonsson Comprehensive Cancer Center · Phase 2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies testing sorafenib in Carcinoma, Hepatocellular — 5 open to participants now, 7 under way, 1 of them phase 3. Sorafenib · Carcinoma, Hepatocellular.

Enrollment
36th of 104
73 · median 44
Started
2012
with 7 others
Phase 2
44 of 104
3 open now
Registered
65th of 104
by date

Among the 104 studies testing sorafenib in Carcinoma, Hepatocellular, this one is the 36th largest by enrollment, is one of 8 that started in 2012, is one of 44 in phase 2, and was the 65th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 104 studies testing sorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About sorafenib

Sorafenib: first FDA approval 2005 (NEXAVAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing sorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation

Read the detailed description

PRIMARY OBJECTIVES:

I. Two-year recurrence free survival (RFS).

SECONDARY OBJECTIVES:

I. One-year recurrence free survival. II. Overall survival (OS). III. Safety. IV. Impact of drug-drug interactions (i.e. immunosuppression agents). V. Impact of biomarkers (alpha-fetoprotein [AFP], protein-induced by vitamin K absence or antagonist II [PIVKA II]).

VI. Effects of therapy on wound healing. VII. Impact of hepatitis C viral recurrence.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive sorafenib tosylate orally (PO) twice daily (BID).

ARM II: Patients receive placebo PO BID.

In both arms treatment continues for 24 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for 2 years.

03

Conditions studied

  • Adult Primary Hepatocellular Carcinoma
  • Localized Resectable Adult Primary Liver Cancer
  • Localized Unresectable Adult Primary Liver Cancer
  • Recurrent Adult Primary Liver Cancer
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have hepatocellular carcinoma (HCC) with one of the following on explant: microvascular/macrovascular invasion, tumor outside of Milan criteria, poor tumor differentiation; patients with macrovascular invasion on explant pathology will be stratified

    * Additionally, the following will be included

    ** Patients with elevated surrogate markers (AFP > 500 or PIVKA > 400) pre transplant and with proven HCC prior to orthotopic liver transplantation (OLT) or on explant

  • (ECOG) performance status (PS) 0-2
  • Patients with a > 12 weeks
  • Patients must have completed prednisone taper within 6 weeks post OLT
  • Patients must be enrolled between 6 to 12 weeks post OLT
  • Cadaveric donors only (no living donor liver transplantation [LDLT] or donor after cardiac death transplantation [DCDT])
  • No sorafenib prior to inclusion in the study
  • count > 50 x 10\^9/L
  • >= 8.5 g/dL
  • Total =\< 5 mg/dL
  • (ALT) and aspartate aminotransferase (AST) =\< 5 x
  • Amylase and lipase =\< 1.5 x the upper limit of normal
  • Serum creatinine \< 2 x the upper limit of normal
  • (PT) =\< 6 seconds or international normalized ratio (INR) =\< 2.3
  • AFP > 500 (pre-transplant)
  • PIVKA > 400 (pre-transplant)
  • Patient has not received prior anti-angiogenic therapy, systemic targeted agents or systemic chemotherapy

    * Prior surgical resection, chemoembolization or other local therapy prior to transplant is permitted

  • Women of must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
  • Patients (men and women) of childbearing potential must agree to use adequate beginning at the signing of the form (ICF) until at least 30 days after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate
  • Patient must be able to swallow and retain oral medication
  • Patient must exhibit the ability to understand and willingness to sign a written informed consent regarding the study and alternative treatments

Exclusion criteria

Exclusion Criteria:

  • Significant ongoing immunologic rejection based on pathology and clinical diagnosis (from time of transplant until randomization)
  • Use of T cell depleting agents for prevention or treatment of rejection at any point prior to or after enrollment in the study
  • Patient with documented evidence of disease
  • 100% tumor necrosis on explant pathology
  • Use of mammalian target of rapamycin (mTOR) inhibitors prior to transplant and as post-transplant
  • Use of alemtuzumab
  • Living donor liver transplant (LDLT) or donation after cardiac death transplant (DCDT)
  • (HIV) positive patients
  • virus (HCV) recurrence at the time of randomization
  • Use of direct acting antivirals for HCV recurrence
  • Requirement of re-transplantation for primary non function
  • Uncontrolled hypertension, defined as systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management
  • Active or cardiac disease including:

    • Congestive heart failure - (NYHA) > class II
    • Coronary artery disease
    • Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin
    • Unstable angina or new-onset angina within 3 months before randomization, or myocardial infarction (MI) within 6 months before randomization
  • Clinically active serious infection documented by positive cultures or an incomplete course of treatment for bacteremia or fungemia
  • Evidence or history of bleeding diathesis or coagulopathy
  • Patients with any pulmonary hemorrhage/bleeding event grade 2 or higher within 4 weeks before randomization
  • Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including [TIAs]) within 6 months before randomization
  • Prior use of raf-kinase inhibitors (sorafenib), vascular endothelial growth factor (VEGF) inhibitors, mitogen-activated protein kinase (MAPK)/extracellular-signal-related kinase (ERK) kinase (MEK) inhibitors, or farnesyl transferase inhibitors
  • Patients using cytochrome P450 3A4 () inducers (eg, phenytoin, carbamazepine, phenobarbital, St. John's Wort dexamethasone) at a dose of greater than 16 mg daily, or rifampin and/or rifabutin within 28 days before randomization
  • Patients with non-HCC except those with DCIS (ductal carcinoma in situ), cervical cancer in-situ, basal cell or superficial bladder tumor; patients surviving a cancer that was curatively treated and without evidence of recurrence for more than 3 years before randomization are allowed
  • Presence of a non-healing wound, non-healing ulcer, or bone fracture
  • Known or suspected allergy or to any of the study drugs, study drug classes, or of the formulations given during the course of this trial
  • Any malabsorption condition
  • Women who are pregnant or breast-feeding
  • Inability to comply with the protocol and/or not willing or not available for follow-up assessments
  • Patients with fibrolamellar HCC, cholangiocarcinoma, and combined HCC-cholangiocarcinoma
  • Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation
  • Prior use of any systemic chemotherapy for HCC
  • Prior use of systemic agents for HCC
  • Prior use of raf-kinase inhibitors (sorafenib), VEGF inhibitors, MEK inhibitors or farnesyl transferase inhibitors
  • Use of biologic response modifiers, such as granulocyte colony-stimulating factor (G-CSF), will not be permitted within 3 weeks prior to study entry; G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity, such as febrile neutropenia, when clinically indicated or at the discretion of the investigator; however, they may not be administered to prevent a dose reduction; patients taking chronic erythropoietin are permitted, provided no dose adjustment is undertaken within 1 month prior to randomization or during the study
  • bone marrow transplant or stem cell rescue within four months of start of study drug
  • Concomitant treatment with rifampin and St. John's wort
  • Concomitant oral mTOR inhibitor treatment
  • Use of direct acting antivirals for HCV recurrence
  • Use of T-cell depleting agents
  • Use of alemtuzumab
  • Anticoagulation, as described below, is allowed:

    • Vitamin-K antagonists (e.g., warfarin)

      ** Low dose warfarin (1 mg orally, once daily) with PT- =\< 1.5 x is permitted; patients taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes

    • Low dose aspirin (=\< 100 mg daily).
    • Heparins and heparinoids Use of any other investigational drug
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Arm I (sorafenib tosylate)

    Patients receive sorafenib tosylate PO BID.

    Drug: sorafenib tosylate · Other: laboratory biomarker analysis

  • Placebo comparator
    Arm II (placebo)

    Patients receive placebo PO BID.

    Other: placebo · Other: laboratory biomarker analysis

Interventions

  • DrugSorafenibStudies of SorafenibSorafenib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN

  • Otherplacebo

    Given PO

    Also known as: PLCB

  • Otherlaboratory biomarker analysis

    Correlative studies

06

What researchers measure

Primary outcomes

  1. Recurrence-free Survival at 2 Years

    Recurrence-free Survival at 2 Years: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.

    Time frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 2 years

Secondary outcomes

  1. Recurrence-free Survival at One Year

    Recurrence-free Survival at One Year: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.

    Time frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 1 year

  2. Overall Survival

    The number of participants who were alive at the last available follow-up. Overall survival was defined as the time from randomization to death from any cause or the last date the participant was known to be alive.

    Time frame: From randomization through the last available follow-up, approximately two years

  3. Graft Failure Free Survival

    Graft Failure Free Survival: The number of participants who remained alive without failure of the transplanted liver. Graft-failure-free survival was defined as the time from randomization to the first documented graft failure according to local clinical standards.

    Time frame: From randomization through the end of study follow-up, approximately two years

  4. Serum Alpha-fetoprotein (AFP) Correlation to Recurrence

    Serum Alpha-fetoprotein (AFP) Correlation to Recurrence: Among participants who experienced hepatocellular carcinoma (HCC) recurrence, this outcome assessed whether serum alpha-fetoprotein (AFP), a blood biomarker used to monitor HCC, was associated with recurrence.

    Time frame: From randomization through the end of study follow-up, approximately two years

  5. Serum Alpha-fetoprotein (AFP) 24 Months

    Serum Alpha-fetoprotein (AFP) 24 Months: Serum alpha-fetoprotein (AFP), a blood biomarker used to monitor hepatocellular carcinoma (HCC), was measured during follow-up. Results are reported as the median AFP level at 24 months.

    Time frame: Assessed at two years

  6. Adverse Events Assessed in Terms of Seriousness, Severity, and Relationship to the Study Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

    See section four, Adverse events and serious adverse events

    Time frame: Assessed from randomization through up to 30 days after last drug dose, approximately two years

  7. Impact of Sorafenib-Tacrolimus Interactions

    Median tacrolimus levels (ng/mL) measured at 24 months

    Time frame: During the 24-month study treatment periodmeasured at 24 months

  8. Wound Complications

    Impact of therapy on wound healing

    Time frame: During the 24-month study treatment period

  9. Hepatitis C Viral Recurrence

    data was insufficient to analyze the impact of Hepatitis C viral recurrence

    Time frame: During the 24-month study treatment period

07

Results

Posted Nov 3, 2026

Participant flow

The study was opened with the first participant patient enrolled (at UCLA) 11/08/2012. The study was closed to accrual on 09/30/2017. High-risk hepatocellular carcinoma-liver transplant recipients were recruited to a phase II multicenter prospective randomized placebo-controlled trial (11-003311/NCT01624285) by 21 initially participating centers across the United States from July 2012 to September 2017.

Treatment Period
Participant flow — Treatment Period
MilestoneArm I (Sorafenib Tosylate)Arm II (Placebo)
Started3043
Completed718
Not completed2325
Withdrew: Adverse event51
Withdrew: Death20
Withdrew: Lack of efficacy24
Withdrew: Lost to follow-up47
Withdrew: Physician decision01
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject911
Follow-up Period
Participant flow — Follow-up Period
MilestoneArm I (Sorafenib Tosylate)Arm II (Placebo)
Started3043
Completed1422
Not completed1621
Withdrew: Death20
Withdrew: Lost to follow-up813
Withdrew: Withdrawal by subject68

Outcome measures

PrimaryRecurrence-free Survival at 2 Years

Recurrence-free Survival at 2 Years: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.

Time frame:
Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 2 years
Reported as:
Count of participants · Participants
Recurrence-free Survival at 2 Years
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Recurrence-free Survival at 2 Years2229
SecondaryRecurrence-free Survival at One Year

Recurrence-free Survival at One Year: The number of participants who were alive without recurrence of hepatocellular carcinoma (HCC). Recurrence-free survival was defined as the time from randomization to the first documented HCC recurrence or death from any cause, whichever occurred first.

Time frame:
Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 1 year
Reported as:
Count of participants · Participants
Recurrence-free Survival at One Year
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Recurrence-free Survival at One Year2332
SecondaryOverall Survival

The number of participants who were alive at the last available follow-up. Overall survival was defined as the time from randomization to death from any cause or the last date the participant was known to be alive.

Time frame:
From randomization through the last available follow-up, approximately two years
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Overall Survival2234
SecondaryGraft Failure Free Survival

Graft Failure Free Survival: The number of participants who remained alive without failure of the transplanted liver. Graft-failure-free survival was defined as the time from randomization to the first documented graft failure according to local clinical standards.

Time frame:
From randomization through the end of study follow-up, approximately two years
Reported as:
Count of participants · Participants
Graft Failure Free Survival
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Graft Failure Free Survival2234
SecondarySerum Alpha-fetoprotein (AFP) Correlation to Recurrence

Serum Alpha-fetoprotein (AFP) Correlation to Recurrence: Among participants who experienced hepatocellular carcinoma (HCC) recurrence, this outcome assessed whether serum alpha-fetoprotein (AFP), a blood biomarker used to monitor HCC, was associated with recurrence.

Time frame:
From randomization through the end of study follow-up, approximately two years
Reported as:
Count of participants · Participants
Serum Alpha-fetoprotein (AFP) Correlation to Recurrence
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Serum Alpha-fetoprotein (AFP) Correlation to Recurrence12
SecondarySerum Alpha-fetoprotein (AFP) 24 Months

Serum Alpha-fetoprotein (AFP) 24 Months: Serum alpha-fetoprotein (AFP), a blood biomarker used to monitor hepatocellular carcinoma (HCC), was measured during follow-up. Results are reported as the median AFP level at 24 months.

Time frame:
Assessed at two years
Reported as:
Median · ng/mL
Serum Alpha-fetoprotein (AFP) 24 Months
ng/mLArm I (Sorafenib Tosylate)Arm II (Placebo)
Serum Alpha-fetoprotein (AFP) 24 Months3.5 (2.3 to 4.8)4.0 (2.0 to 6.7)
SecondaryAdverse Events Assessed in Terms of Seriousness, Severity, and Relationship to the Study Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

See section four, Adverse events and serious adverse events

Time frame:
Assessed from randomization through up to 30 days after last drug dose, approximately two years
Reported as:
Count of participants · Participants
Adverse Events Assessed in Terms of Seriousness, Severity, and Relationship to the Study Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Adverse Events Assessed in Terms of Seriousness, Severity, and Relationship to the Study Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.02434
SecondaryImpact of Sorafenib-Tacrolimus Interactions

Median tacrolimus levels (ng/mL) measured at 24 months

Time frame:
During the 24-month study treatment periodmeasured at 24 months
Reported as:
Median · ng/mL
Impact of Sorafenib-Tacrolimus Interactions
ng/mLArm I (Sorafenib Tosylate)Arm II (Placebo)
Impact of Sorafenib-Tacrolimus Interactions5.5 (5 to 7.1)5.4 (3.5 to 7.075)
SecondaryWound Complications

Impact of therapy on wound healing

Time frame:
During the 24-month study treatment period
Reported as:
Count of participants · Participants
Wound Complications
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Wound Complications10
SecondaryHepatitis C Viral Recurrence

data was insufficient to analyze the impact of Hepatitis C viral recurrence

Time frame:
During the 24-month study treatment period
Reported as:
Count of participants · Participants
Hepatitis C Viral Recurrence
ParticipantsArm I (Sorafenib Tosylate)Arm II (Placebo)
Hepatitis C Viral Recurrence01

Adverse events

Collected over up to 30 days after the last study drug dose.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I (Sorafenib Tosylate)2/24 (8.3%)21/24 (87.5%)24/24 (100%)
Arm II (Placebo)0/34 (0%)31/34 (91.2%)34/34 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventArm I (Sorafenib Tosylate)Arm II (Placebo)
NauseaGastrointestinal disorders0/243/34
Liver transplant rejectionImmune system disorders2/240/34
Metastatic hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/240/34
Flank painGeneral disorders0/242/34
Transaminases increasedInvestigations0/242/34
Atrial fibrillationCardiac disorders1/240/34
AscitesGastrointestinal disorders1/240/34
ColitisGastrointestinal disorders1/240/34
FeverGeneral disorders1/240/34
JaundiceHepatobiliary disorders1/240/34
Most frequent other events
Showing 10 of 159
Most frequent other events
EventArm I (Sorafenib Tosylate)Arm II (Placebo)
DiarrheaGastrointestinal disorders16/247/34
HypertensionVascular disorders10/248/34
LeukopeniaBlood and lymphatic system disorders5/241/34
NauseaGastrointestinal disorders5/244/34
Peripheral edemaGeneral disorders5/242/34
PruritusSkin and subcutaneous tissue disorders5/243/34
RashSkin and subcutaneous tissue disorders5/241/34
Abdominal painGastrointestinal disorders4/246/34
FatigueGeneral disorders4/246/34
ThrombocytopeniaBlood and lymphatic system disorders4/240/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm I (Sorafenib Tosylate)Arm II (Placebo)Total
Median63 (58 to 66)62 (59 to 67)62 (58 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Arm I (Sorafenib Tosylate)Arm II (Placebo)Total
Female527
Male193251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm I (Sorafenib Tosylate)Arm II (Placebo)Total
Hispanic or Latino549
Not Hispanic or Latino000
Unknown or Not Reported193049
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I (Sorafenib Tosylate)Arm II (Placebo)Total
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American101
White193049
More than one race000
Unknown or Not Reported022
Region of Enrollment
Region of Enrollment(participants)Arm I (Sorafenib Tosylate)Arm II (Placebo)Total
United States243458
MELD (Model for End Stage-Liver Disease) Score
MELD (Model for End Stage-Liver Disease) Score(units on a scale)Arm I (Sorafenib Tosylate)Arm II (Placebo)Total
Median28 (24 to 31)28 (22 to 33)28 (22 to 33)
Indication for Liver Transplant (LT)
Indication for Liver Transplant (LT)(Participants)Arm I (Sorafenib Tosylate)Arm II (Placebo)Total
Primary Hepatocellular Carcinoma (HCC)5914
End Stage Liver Disease + Primary Hepatocellular Carcinoma: ESLD+HCC192544
08

Study locations

21 sites
  • University of Alabama
    Birmingham, Alabama 35294-0007, United States
  • Jonsson Comprehensive Cancer Center
    Los Angeles, California 90095, United States
  • University of Colorado
    Denver, Colorado 80217-3364, United States
  • Mount Sinai Hospital
    Hartford, Connecticut 06112, United States
  • Lombardi Comprehensive Cancer Center at Georgetown University
    Washington D.C., District of Columbia 20057, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287-8936, United States
  • Lahey Clinic Medical Center
    Burlington, Massachusetts 01805, United States
  • University of Michigan University Hospital
    Ann Arbor, Michigan 48109, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-7830, United States
  • University of Pennsylvania Health System
    Cherry Hill, New Jersey 08034, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • New York Presbyterian-The University Hospital of Columbia and Cornell
    New York, New York 10065, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Integris-Baptist Medical
    Oklahoma City, Oklahoma 73112, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • The Methodist Hospital Research Institute
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Feb 2023, 123 months.

Results were first posted in Nov 2026, 3 years 9 months after primary completion.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's 123 months is above that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

Start moved once since we started tracking on Sep 25, 2026: Jul 2012 → Nov 2012, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2012
First posted
Jun 20, 2012
StartActual
Nov 8, 2012was Jul 2012
Primary completionActual
Feb 2023
CompletionActual
Feb 2023
Results first posted
Nov 3, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 3, 2026
Sites
1 site added, 1 site removed
Show site
  • Lombardi Comprehensive Cancer Center at Georgetown University · Washington D.C., United States
Show 1 removed
  • Lombardi Comprehensive Cancer Center at Georgetown University · Washington, United States
Nov 3, 2026
Start date
Jul 16, 2012→Nov 8, 2012
Nov 3, 2026
Enrollment
20→73
Nov 3, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) CommitteeNow Recurrence-free Survival at 2 YearsTime frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 2 years
Nov 3, 2026
Secondary outcomes
3 edited, 6 added, 4 removed
What changed in the outcomes
  • EditedOverall survivalSurvivalTime frame: From randomization to the date of death or the last date the subject was known to be alive, assessed up to 2 years after completion of study treatment → From randomization through the last available follow-up, approximately two years
  • EditedAdverse events assessedEvents Assessed in termsTerms of seriousnessSeriousness, severitySeverity, and relationshipRelationship to the study material accordingStudy Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) versionVersion 4.0Time frame: Assessed up to 2 years → Assessed from randomization through up to 30 days after last drug dose, approximately two years
  • EditedImpact of drugSorafenib-drug interactionsTacrolimus InteractionsTime frame: Assessed up to 2 years after completion of study treatment → During the 24-month study treatment periodmeasured at 24 months
  • AddedRecurrence-free Survival at One YearTime frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 1 year
  • AddedGraft Failure Free SurvivalTime frame: From randomization through the end of study follow-up, approximately two years
  • AddedSerum Alpha-fetoprotein (AFP) Correlation to RecurrenceTime frame: From randomization through the end of study follow-up, approximately two years
  • AddedSerum Alpha-fetoprotein (AFP) 24 MonthsTime frame: Assessed at two years
  • AddedWound ComplicationsTime frame: During the 24-month study treatment period
  • AddedHepatitis C Viral RecurrenceTime frame: During the 24-month study treatment period
  • RemovedRecurrence-free survival, evaluated using the new international criteria proposed by the mRECIST CommitteeTime frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 1 year
  • RemovedImpact of biomarkers (AFP and PIVKA II)Time frame: Assessed up to 2 years after completion of study treatment
  • RemovedTime to wound healingTime frame: Assessed up to 2 years after completion of study treatment
  • RemovedTime to first HCV viral recurrenceTime frame: Assessed up to 2 years after completion of study treatment
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Lombardi Comprehensive Cancer Center at Georgetown University · Washington D.C., United States
    Show 1 removed
    • Lombardi Comprehensive Cancer Center at Georgetown University · Washington, United States
    Start date Jul 16, 2012→Nov 8, 2012
    Enrollment 20→73
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Recurrence-free survival, evaluated using the new international criteria proposed by the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) CommitteeNow Recurrence-free Survival at 2 YearsTime frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 2 years
    Secondary outcomes 3 edited, 6 added, 4 removed
    What changed in the outcomes
    • EditedOverall survivalSurvivalTime frame: From randomization to the date of death or the last date the subject was known to be alive, assessed up to 2 years after completion of study treatment → From randomization through the last available follow-up, approximately two years
    • EditedAdverse events assessedEvents Assessed in termsTerms of seriousnessSeriousness, severitySeverity, and relationshipRelationship to the study material accordingStudy Material According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) versionVersion 4.0Time frame: Assessed up to 2 years → Assessed from randomization through up to 30 days after last drug dose, approximately two years
    • EditedImpact of drugSorafenib-drug interactionsTacrolimus InteractionsTime frame: Assessed up to 2 years after completion of study treatment → During the 24-month study treatment periodmeasured at 24 months
    • AddedRecurrence-free Survival at One YearTime frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 1 year
    • AddedGraft Failure Free SurvivalTime frame: From randomization through the end of study follow-up, approximately two years
    • AddedSerum Alpha-fetoprotein (AFP) Correlation to RecurrenceTime frame: From randomization through the end of study follow-up, approximately two years
    • AddedSerum Alpha-fetoprotein (AFP) 24 MonthsTime frame: Assessed at two years
    • AddedWound ComplicationsTime frame: During the 24-month study treatment period
    • AddedHepatitis C Viral RecurrenceTime frame: During the 24-month study treatment period
    • RemovedRecurrence-free survival, evaluated using the new international criteria proposed by the mRECIST CommitteeTime frame: Defined as the time from randomization to the first documented disease recurrence by radiological assessment or death due to any cause whichever occurs first, assessed at 1 year
    • RemovedImpact of biomarkers (AFP and PIVKA II)Time frame: Assessed up to 2 years after completion of study treatment
    • RemovedTime to wound healingTime frame: Assessed up to 2 years after completion of study treatment
    • RemovedTime to first HCV viral recurrenceTime frame: Assessed up to 2 years after completion of study treatment
    + 2 other changes: index terms and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01624285
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jun 20, 2012
Start date
Nov 8, 2012
Primary completion
Feb 2023
Completion
Feb 2023
Results posted
Nov 3, 2026
Last update
Nov 3, 2026

Study contacts

Fady Kaldas, MD
principal investigator · Jonsson Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sorafenib

Start the discussion